AA6

GDS Announces Repurchase of US$299,910,000 of 2.00% Convertible Senior Notes due 2025

Retrieved on: 
Thursday, June 1, 2023
Exercise, Bank, Debt-to-GDP ratio, Note, BNY Mellon, AA6, AB4, GDS, Indenture, Car rental, Property management

SHANGHAI, China, June 01, 2023 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced that it repurchased approximately US$299,910,000 aggregate principal amount of its 2.00% Convertible Senior Notes due 2025 (CUSIP Nos.

Key Points: 
  • SHANGHAI, China, June 01, 2023 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China and South East Asia, today announced that it repurchased approximately US$299,910,000 aggregate principal amount of its 2.00% Convertible Senior Notes due 2025 (CUSIP Nos.
  • 36165L AA6, 36165L AB4 & G3902L AA7) (the “Notes”).
  • The repurchases were consummated through holders’ exercise of the Repurchase Right.
  • None of the Company, its board of directors or its employees has made or is making any representation or recommendation to any holder of the Notes.

Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting

Retrieved on: 
Wednesday, May 18, 2022
Editas Medicine, DNA, Company, Doctor of Philosophy, U.S. Securities and Exchange Commission, Survival, Neoplasm, AA6, Nasdaq, Gold, Abstract (summary), Private Securities Litigation Reform Act, Gene editing, Clinical trial, Society, Cell, Canadian Aviation Regulations, Selection, Gene, Time, NK, Application Session Controller, CRISPR, RHO, Technology, Ovarian cancer, Birth defect, CD16, Multiplexing, Cancer, Potency (pharmacology), Annual report, GLOBE, Vaccine, Pharmaceutical industry, Cpf1

CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present data later today on its SLEEK (SeLection by Essential- gene Exon Knock-in) gene editing technology during the New Gene Editing Technologies and Applications Session at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held in Washington, D.C., and virtually, May 16 – 19, 2022.

Key Points: 
  • We have used SLEEK to achieve very high knock-in efficiencies in T cells, B cells and natural killer (NK) cells.
  • Further key findings presented about SLEEK include:
    Enables knock-in editing efficiencies of over 90% in relevant cell types, without impacting long-term viability or expansion.
  • Permits constitutive and robust expression in iPSC-derived cell types where transgene promoter silencing has been a major challenge during the differentiation process.
  • Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases.

Domtar Corporation Announces the Expiration of the Change of Control Offers to Purchase Its 6.25% Senior Notes Due 2042 and Its 6.75% Senior Notes Due 2044

Retrieved on: 
Wednesday, January 5, 2022
Packaging, Other Natural Resources, Forest Products, Manufacturing, Natural Resources, Other Manufacturing, Corporation, Expiration, Debt-to-GDP ratio, COVID-19, Expiration date, Transport, Weather, REG, Unsecured debt, AA6, Redemption, Failure, Fire, Company, Communication, Asset-backed security, Pacific typhoon season, Note, Nisio Isin, Goal, U.S. Securities and Exchange Commission, Lists of disasters, Annual report, CUSIP, Private Securities Litigation Reform Act, Paper Excellence, SEC, FICC, Senior, Virus, Forestry, Offers, Risk, Depository Trust Company, Multimedia, Flood, Maintenance, Investment, Paper, Security (finance), Bank, Risk management, Domtar, Mergers and acquisitions

Domtar Corporation (the Company) today announced the expiration of its previously announced offers to purchase (the Offers) any and all of its outstanding 6.25% Senior Notes due 2042 (CUSIP No.

Key Points: 
  • Domtar Corporation (the Company) today announced the expiration of its previously announced offers to purchase (the Offers) any and all of its outstanding 6.25% Senior Notes due 2042 (CUSIP No.
  • US257559AJ34) (the 2042 Notes) and 6.75% Senior Notes due 2044 (CUSIP No.
  • US257559AK07) (the 2044 Notes and, together with the 2042 Notes, the Unsecured Notes).
  • The Company intends to pay for all Unsecured Notes delivered and not validly withdrawn pursuant to the Offers on January 7, 2022.